Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is BillionToOne (BLLN) Stock Down 8.04% Today?

Why Is BillionToOne (BLLN) Stock Down 8.04% Today?

Key Takeaways

  • Shares of BLLN fell 8.04% to $89.66 in mid-morning trade, down from the prior close of $97.50, after touching an intraday low of $85.71.
  • The primary catalyst is a short-seller report from Fuzzy Panda Research, published before the opening bell, alleging improper billing practices and undisclosed regulatory scrutiny at the molecular diagnostics company.
  • Secondary pressure: questions over the clinical differentiation of its Northstar cancer tests, rising days sales outstanding, and a bear-case model implying roughly 80% downside to EBITDA if carrier-screening claims were curtailed.
  • The selloff is company-specific: healthcare peers and broad indices held up far better, with the sector ETF down less than 1% and large diagnostics names roughly flat.
  • The stock is now about 22% below its Nov. 9 close of $114.95, extending a slide that began after a strong third-quarter report failed to satisfy reimbursement-focused investors.
  • News Significance Score: 50/100 — Serious but unproven short-seller allegations met a move nearly three times the stock's typical daily swing.
  • Traders are watching for a formal company response, Medicare coverage decisions for Northstar Response, and the Dec. 15 launch of Northstar Clear.
  • For deeper detail on BLLN, explore the Price Targets, Earnings, and Forecast pages.
  • Readers can also review Trending AI Robots for strategies currently performing best in this market.

Opening Summary

BillionToOne, Inc. (BLLN) is a Menlo Park, California–based molecular diagnostics company whose single-molecule counting platform powers UNITY prenatal screening and the Northstar liquid biopsy franchise for oncology. Its shares traded at $89.66 shortly after 10 a.m. ET on Wednesday, a decline of 8.04% from Tuesday's closing price of $97.50. The direction is clearly negative, and the move is idiosyncratic rather than sector-driven: a critical short-seller report published before the open alleged improper billing, undisclosed state-level scrutiny and weaker clinical differentiation than management claims.

Short-Seller Report Hits Before the Open

Fuzzy Panda Research disclosed a short position in BLLN and published a report built on state public-records requests, interviews with anonymous former employees and conversations with physicians. The most consequential allegation concerns Tennessee Medicaid: the report says state records show an integrity inquiry opened in 2024 after 11 tips and was referred to the Tennessee Bureau of Investigation's Medicaid fraud unit, and that billing records reflect the use of unlisted CPT codes reimbursed at roughly ten times standard rates. It also questions why that scrutiny never appeared in the company's securities filings.

A second thread examines Michigan Medicaid data, claiming the company billed once-in-a-lifetime genetic carrier screening alongside about 88% of its non-invasive prenatal tests — well above the roughly 40% of pregnancies involving first-time mothers — and that sales staff capped patient deductibles and copays between $99 and $349 without income verification. BillionToOne has not publicly responded, and a referral to a law enforcement agency does not establish wrongdoing; no charges or regulatory findings exist.

Valuation, Reimbursement and Momentum Collide

The report's financial framing matters more than the individual anecdotes for a company valued near $4.3 billion. Fuzzy Panda estimated that curbing carrier-screening claims it deems excessive could erase about 80% of EBITDA, and modeled hypothetical False Claims Act exposure above $1.2 billion — its own estimate, not a booked liability. The report also flags rising days sales outstanding and insurer disputes, and cites oncologists skeptical of Northstar's differentiation, on top of alleged undisclosed prenatal false negatives.

That lands on an already fragile narrative. Third-quarter revenue of $123 million, up 47% year over year, and raised 2026 guidance of $460 million to $470 million were well received on Nov. 4, yet the stock still sold off as investors fixated on the timing of Medicare coverage for Northstar Response, PAMA reimbursement changes and the durability of true-up revenue. Wednesday's report simply gave that caution a sharper edge and forced a repricing of revenue quality rather than growth.

Market Context and Trading Activity

Turnover was heavy, with roughly 154,000 shares changing hands in the first half hour — a pace well ahead of the stock's typical daily volume. The move diverged sharply from the tape: the health care sector ETF slipped about 0.85% and the Nasdaq-100 rose 0.7%, while diagnostics peers were mixed, with NTRA down 1.33%, GH and TEM roughly flat and MYGN up 1.44%. Technically, BLLN had already lost its 50-day moving average near $104 and the $96 support area earlier this week; Wednesday's dip to $85.71 marked its lowest intraday print since mid-August, and the stock remains far below its 52-week high of $150.44.

News Significance Score

The score runs from 0, meaning no meaningful news and an ordinary move for the stock, to 100, meaning transformative news and a rare, extreme price move. This event earns 50 out of 100.

A named short-seller report alleging billing irregularities, undisclosed investigative scrutiny and roughly 80% EBITDA risk is substantial relative to a $4.3 billion company, but the claims are unproven and no regulator has issued findings. The price reaction was meaningful but not historic: today's 8.04% decline is about 2.9 times the stock's average absolute daily move of 2.77% over the past 60 sessions, and moves of similar or greater size occurred five times in that span. A strong news component paired with a moderately unusual move produces the mid-range score.

What Comes Next for BLLN

The immediate focus is whether management issues a detailed rebuttal, since the allegations now sit alongside a reimbursement story that already concerned investors. Fourth-quarter and full-year 2026 results are expected in early March 2027, and the Dec. 15 commercial launch of Northstar Clear, a tissue-free minimal residual disease test, will be the next hard datapoint on the oncology franchise. Also in view: Medicare coverage timing for Northstar Response, PAMA-related reimbursement shifts, days-sales-outstanding trends, and any analyst revisions to revenue-quality assumptions. Risks cut both ways — a credible rebuttal could stabilize the shares, while regulatory escalation or insurer pushback would keep pressure on a stock still trading near triple-digit earnings multiples.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics and traded symbols, so the lineup shifts as conditions change. Reviewing the current leaders is a practical way to see how automated strategies are positioned right now — explore the page to find the bots best suited to your approach.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BLLN

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for BLLN turns negative, indicating new downward trend

BLLN saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator turned negative. In 19 of the 21 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BLLN turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

BLLN moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BLLN crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 1 of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

The Aroon Indicator for BLLN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for BLLN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 48 of 54 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

BLLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. BLLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.016) is normal, around the industry mean (67.298). BLLN has a moderately high P/E Ratio (136.508) as compared to the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -8%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 20%. VCYT experienced the highest price growth at 2%, while IMDX experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 51
SMR Rating: 78
Profit Risk Rating: 87
Seasonality Score: 26 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Industry
N/A
Address
1035 O’Brien Drive
Phone
+1 650 460-2551
Employees
713
Web
https://www.billiontoone.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.